Exercise as medicine: new trial tests if tailored workouts boost Well-Being in leukemia patients
NCT ID NCT06299540
First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 3 times
Summary
This study is testing whether a personalized physical activity program can improve the quality of life for people with chronic lymphocytic leukemia (CLL) who are starting treatment with ibrutinib. The program includes 4 months of supervised exercise followed by 2 months of independent activity. Researchers will measure changes in well-being using standard questionnaires. The trial aims to enroll 180 participants in real-world clinic settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Individual Physical Activity Intervention (IPAI)
- What this could lead to
- If it works, this could show that a tailored exercise program helps people with CLL feel better and have a higher quality of life while on ibrutinib.
- What could go wrong
- This is a relatively small, early-stage study focused on quality of life, not on curing the disease. The benefits may vary widely between individuals, and the program requires motivation and access to technology.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Universitaire du Cancer Toulouse Oncopole
RECRUITINGToulouse, 31059, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for tough blood cancers: early trial of ONO-7018 begins
- New combo therapy for CLL tested in Real-World settings
- New CLL strategy: give extra drug only to those who still have cancer cells
- New pill shows promise for Hard-to-Treat blood cancers
- New pill shows promise for Hard-to-Treat leukemia and lymphoma
- Engineered immune cells take on tough leukemias